NIH describes the cardiovascular implications as uncertain but concerning enough to discuss with a clinician if you have heart disease risk, high LDL cholesterol, kidney disease, or plan to use high doses for months
Post-marketing surveillance and case reports have documented isolated instances of patients reporting muscle pain, cramping, or weakness while taking GLP-1 medications, though establishing a direct causal relationship remains challenging
Clin Dermatol 7(4):7892
If you walk in expecting to gain ten pounds of muscle from BPC-157 alone, you will be disappointed
KK has received honoraria for lectures/advisory boards and research support from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk
Continuous use beyond 6 weeks leads to IGF-1 receptor downregulation (decreased density and sensitivity)